Stock AMLX AMYLYX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Amylyx Pharmaceuticals, Inc.

Equities

AMLX

US03237H1014

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-05-03 EDT 		5-day change 1st Jan Change
2.03 USD +1.50% Intraday chart for Amylyx Pharmaceuticals, Inc. +15.34% -86.21%
04-11 Baird Trims Amylyx Pharmaceuticals' Price Target to $3 From $4, Maintains Neutral Rating MT
04-10 Transcript : Amylyx Pharmaceuticals, Inc. - Special Call

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Amylyx Pharmaceuticals Announces Interim Data from Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Sector Update: Health Care Stocks Mixed in Afternoon Trading
Top Midday Stories: Ford Delays Start of EV Production at Canadian Plant; Alphabet Mulls Acquiring HubSpot; Boeing Paid Alaska Airlines $160 Million in Q1 for Fleet Grounding; Taiwan Semiconductor Expects Full Recovery of Top Plant on Thursday; Coinbase Registered as Restricted Dealer in Canada; CSX Completes First Shipments Using New Rail Post Baltimore Bridge Collapse; Levi Shares Soar on Earnings Beat; Amylyx to Discontinue Marketing Authorizations for Relyvrio
Amylyx Pharmaceuticals to Discontinue Relyvrio/Albrioza in US, Canada; Slashes Workforce by 70%
Amylyx Pharmaceuticals, Inc. Announces Formal Intention to Remove Relyvrio/Albriza from the Market
Sector Update: Health Care Stocks Edge Up Late Monday Afternoon
Top Midday Decliners
Amylyx Pharmaceuticals, Inc. Appoints Bernhardt Zeiher to Its Board of Directors
Sector Update: Health Care Stocks Ease Late Afternoon
Top Midday Decliners
Sector Update: Health Care Stocks Lower Friday Afternoon
Sector Update: Health Care Stocks Steady Pre-Bell Friday
February Jobs Report Drives Muted Premarket Action for US Equity Futures
Sector Update: Health Care
Amylyx's Phase 3 Amyotrophic Lateral Sclerosis Trial Misses Endpoints; Shares Drop
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Ahead of Key Jobs Report
Top Premarket Decliners
Amylyx Pharmaceuticals, Inc. Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
Amylyx Pharmaceuticals Swings to Q4 Profit, Net Product Revenue Increases; Shares Rise
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMLX Stock
  4. News Amylyx Pharmaceuticals, Inc.
  5. Other languages